Thrombosis Research Institute (TRI) to Announce New Real-World Insights in Atrial Fibrillation at ESC Congress 2018 - Seite 2

variety of results, including new insights on the quality of stroke
prevention and its clinical effectiveness in routine care, and
presentations on the real-world record of change in prescribing
practice and outcomes. The new GARFIELD-AF risk score and its online
application will also be discussed. The symposium will also include a
panel discussion led by Professors Jean-Pierre Bassand (France) and
Samuel Z. Goldhaber (USA).

Other key data from GARFIELD-AF will be presented during the
following sessions:

Rapid Fire Abstract Session entitled 'Atrial fibrillation -
Detection, treatment, outcomes' - (11:00 - 12:30, Sunday 26th August;
Location: Agora 2 - Agora)

"The effect of non-recommended dosing of non-vitamin K antagonist
oral anticoagulants (NOACs) on 1-year mortality in patients with
newly diagnosed AF. Results from the GARFIELD-AF registry."

Professor John Camm (UK) will highlight the impact of using
non-recommended doses of NOACs for stroke prevention in in patients
with newly diagnosed AF.

Poster Session 3 - (14.00 - 18.00, Sunday 26th August)

Evaluation of the effect of oral anticoagulants on all-cause
mortality within 3 months of the diagnosis of atrial fibrillation

Karen Pieper (USA) will reveal significant early mortality in
patients with newly diagnosed AF and significant mortality
differences in favour of OACs, even after adjustment for 29 baseline
variables.

The economic burden attributable to atrial fibrillation in nine
European countries

Paolo Cozzolino (Italy) will report that the economic burden of
AF, a growing public health problem, correlates with differences in
management between countries.

Poster Session 5 - (14.00 - 18.00, Monday 27th August)

Why do clinicians withhold anticoagulation in patients with atrial
fibrillation and CHA2DS2-VASc score >=2?

Dr Deborah Siegal (Canada) will report that guideline-based
treatment with oral anticoagulants was associated with better
outcomes, results that emphasise the need to better understand
decision-making to improve oral anticoagulant prescription rates and
outcomes in AF.

Why do clinicians prescribe oral anticoagulation in patients with
atrial fibrillation despite a low CHA2DS2-VASc score?

Frederik Verbrugge (Belgium) will report on the discrepancy
between patient characteristics that predict OAC use in AF patients
with a very low CHA2DS2-VASc score and factors reported by clinicians
that influence their decision-making.

About the GARFIELD-AF registry

GARFIELD-AF is a worldwide observational programme that aims to
enhance the breadth and depth of understanding of stroke prevention